Hengrui Medicine issues H-share listing hearing materials

Jiangsu Hengrui Medicine (SSE:600276) has released its post-hearing information package related to its proposed issuance of overseas listed foreign shares (H shares) and listing on the Hong Kong Stock Exchange (HKEX). The company submitted its listing application to the HKEX on January 6, 2025, and received approval from the China Securities Regulatory Commission on April 28, 2025 (Guo He Han [2025] 721). The HKEX Listing Committee reviewed the application on April 30, 2025. The post-hearing information, intended for Hong Kong public and qualified investors, is available on the HKEX website. Hengrui Medicine cautions that the information is preliminary and subject to change, and will not be published on domestic exchanges or media. The company emphasized that the offering is subject to approvals from the Hong Kong Securities and Futures Commission and the HKEX.